Novan to Participate in the Virtual Investor Roundtable Event
Novan, Inc. (Nasdaq: NOVN) will host a Virtual Investor Roundtable Event on November 17, 2021, at 1:00 PM ET, featuring CEO Paula Brown Stafford and a pediatric dermatology expert.
The event will include a presentation, a moderated discussion, and a live Q&A session, allowing investors to submit questions. The webcast will be accessible on the Company's website and will be available for replay for one year.
Novan focuses on developing nitric oxide-based therapies in dermatology and anti-infective treatments.
- None.
- None.
– Live moderated video webcast discussion among management and Pediatric Dermatology Thought Leader on Wednesday, November 17th at 1:00 PM ET –
DURHAM, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, joined by a pediatric dermatology thought leader, will participate in the Virtual Investor Roundtable Event on Wednesday, November 17, 2021 at 1:00 PM ET.
As part of the virtual event, the Company will provide a brief presentation, followed by a moderated roundtable discussion and an interactive Q&A session where all investors and interested parties will have the opportunity to submit questions live during the event. Interested parties may also pre-submit questions in advance of the live event, which can be sent via the conference website at virtualinvestorco.com. The Company will answer as many questions as possible during the event.
A live video webcast of the Roundtable Event will be available on the Events page of the Investors section of the Company’s website (novan.com). A webcast replay will be available two hours following the live presentation and will be accessible for one year.
About Novan
Novan, Inc. is a pre-commercial nitric oxide-based pharmaceutical company focused on dermatology and anti-infective therapies. We leverage our core synergies of science, capital, resources and patient needs to create value by bringing new nitric oxide-based medicines to market. Our goal is to create the world’s leader in nitric oxide-based science, technology, and clinical translation in support of delivering safe and efficacious therapies using our proprietary nitric oxide-based technology platform, NITRICIL™ to generate macromolecular New Chemical Entities (NCEs) to treat multiple indications.
INVESTOR AND MEDIA CONTACT:
Jenene Thomas
JTC Team, LLC
833-475-8247
NOVN@jtcir.com
FAQ
When is Novan's Virtual Investor Roundtable Event?
Who will participate in Novan's investor event?
How can I view Novan's investor webcast?
Will the Novan investor event include a Q&A session?
What is Novan's focus in the pharmaceutical industry?
